Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 5

WCLC Updates in Locally Advanced NSCLC

, , ,

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).

EP. 1: WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
EP. 2: WCLC Updates on the Emergence of ADCs in NSCLC
EP. 3: WCLC Updates in Immunotherapy for NSCLC
EP. 4: WCLC Updates in Neoadjuvant Therapy for NSCLC
Now Viewing
EP. 5: WCLC Updates in Locally Advanced NSCLC
EP. 6: WCLC Updates in Small Cell Lung Cancer

Data from the following clinical trial are discussed: 

  •  OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced Stage III NSCLC: KEYNOTE-799

Related Content:

Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung CancerLung Cancer
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation
Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases
Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC